Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States.
The last earnings update was 55 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Menlo Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Menlo Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Menlo Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Menlo Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Menlo Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Menlo Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Menlo Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Menlo Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Menlo Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Menlo Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Steven L. Basta, also known as Steve, has been Chairman of Viveve Medical, Inc. since January 16, 2019. He has been the Chief Executive Officer, President and Director of Menlo Therapeutics Inc. since September 2015. Mr. Basta has been Director of Viveve Medical Inc. since September 13, 2018. Mr. Basta is a Business Advisor at Spindletop Capital. Previously, he served as a Member of Executive Council and Venture Partner at the firm. Mr. Basta served as the Chief Executive Officer of AlterG, Inc. from October 2011 to August 2015. Before joining AlterG, he led several emerging biopharmaceutical and medical device companies. He served as the Chief Executive Officer of Merz Aesthetics, Inc. from November 2002 to September 2011 and served as its President from December 2000 to June 2007. From November 2002 to February 2010, he served as Chief Executive Officer of BioForm Medical, Inc. He served as Vice President of Finance and Business Development at Curis, Inc. He joined Merz Aesthetics, Inc. in December 2000. He served as the President and Chief Executive Officer of Gliatech Inc. since December 2000. Prior to joining Gliatech Inc., he served as Treasurer of Creative Biomolecules Inc. He served as Vice President of Finance and Business Development and Chief Financial Officer of Creative BioMolecules, Inc. from January 1999 to August 2000 and served as its Vice President of Corporate Development & Investor Relations from February 1997 to January 1999. He was associated with Jundt Associates from June 1996 to December 1996. From September 1990 to June 1996, he held several positions with The Immune Response Corporation, including an Executive Director of Product Development from 1994 to 1996, Program Director for an HIV research joint venture from 1992 to 1993 and Director of Investor Relations & Market Development from 1991 to 1992. He served as an Associate with Dillon, Read & Co, Inc. from 1988 to 1990, where he began his career. He served as a Director of RF Surgical Systems, Inc from December 2013 to August 2015. He served as a Director of Carbylan Therapeutics, Inc., since September 2009 to November 2016. He served as a Director of Merz Aesthetics, Inc. since November 2002, AlterG, Inc. from November 2002 to September 7, 2015 and Gliatech Inc. since February 2001. He served as Director of KalVista Pharmaceuticals, Inc until November 22, 2016. Mr. Basta received a B.A. in Bio Medical Engineering from The Johns Hopkins University and an MBA from the Kellogg Graduate School of Business at Northwestern University.
Steve's compensation has increased whilst company is loss making.
Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Menlo Therapeutics management team is about average.
Senior VP of Corporate Strategy & CFO
Chief Medical Officer
Chief Scientific Officer
Vice President of Business Development
Senior Vice President of Non-Clinical & Pharmaceutical Development
Senior Vice President of Medical Affairs
Senior Vice President of Commercial Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Menlo Therapeutics board of directors is about average.
How Financially Strong Is Menlo Therapeutics Inc. (NASDAQ:MNLO)?
(NASDAQ:MNLO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … While MNLO has no debt on its balance sheet, it doesn’t necessarily mean it exhibits financial strength. … Is MNLO right in choosing financial flexibility over lower cost of capital.
What You Must Know About Menlo Therapeutics Inc's (NASDAQ:MNLO) Financial Strength
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is MNLO growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding
Menlo Therapeutics Inc (NASDAQ:MNLO): Is Breakeven Near?
Menlo Therapeutics Inc's (NASDAQ:MNLO):. … Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. … Many investors are wondering the rate at which MNLO will turn a profit, with the big question being “when will the company breakeven?”
Does Menlo Therapeutics Inc's (NASDAQ:MNLO) Past Performance Indicate A Weaker Future?
Assessing Menlo Therapeutics Inc's (NASDAQ:MNLO) past track record of performance is a useful exercise for investors. … View our latest analysis for Menlo Therapeutics How Did MNLO's Recent Performance Stack Up Against Its Past? … For Menlo Therapeutics, its latest earnings (trailing twelve month) is -US$29.08M, which, against the prior year's figure, has become more negative.
Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis; psoriasis; chronic pruritus; atopic dermatitis; and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.